Beijing Leadman Biochemistry Co., Ltd. Class A

Beijing Leadman Biochemistry Co., Ltd. Class A

SSZSE:300289
5.94
CNY
-0.09
(-1.49%)
0.01EPS
3.30BMarket Cap

Total Valuation

CNY

As of September 30, 2026, Beijing Leadman Biochemistry Co., Ltd. Class A carries a market capitalization of 3.30B, placing it among publicly traded companies globally. Its enterprise value stands at 4.18B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap3.30B
Enterprise Value4.18B

Share Statistics

As of September 30, 2026, Beijing Leadman Biochemistry Co., Ltd. Class A has 544.01M shares outstanding.

Shares Outstanding544.01M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 6.78, and the price-to-book ratio stands at 2.00.

PS Ratio6.78
PB Ratio2.00
P/TBV Ratio4.42

Enterprise Valuation

As of September 30, 2026, Beijing Leadman Biochemistry Co., Ltd. Class A trades at an EV/EBITDA multiple of 250.39 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 8.60 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 250.39 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 4.18B versus a market cap of 3.30B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales8.60
EV / EBITDA250.39
EV / EBIT250.39

Financial Position

As of September 30, 2026, Beijing Leadman Biochemistry Co., Ltd. Class A maintains a current ratio of 4.28, meaning it holds 4.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 46.31, indicating elevated leverage, while an interest coverage ratio of 2.94 demonstrates limited ability to service its debt obligations.

Current Ratio4.28
Quick Ratio1.31
Debt / Equity46.31
Debt / EBITDA58.86
Interest Coverage2.94

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Beijing Leadman Biochemistry Co., Ltd. Class A posted a negative return on equity (ROE) of -0.54, meaning shareholder capital produced losses rather than profits. Return on invested capital (ROIC) comes in at 0.30 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) is negative at -0.33, reflecting losses generated across the asset base. Return on capital employed (ROCE) is negative at -0.93, pointing to unprofitable operations over the period. The company generates approximately 1.16M in revenue per employee across its workforce of 420.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.20 indicates how many times Beijing Leadman Biochemistry Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-0.54
Return on Assets (ROA)-0.33
Return on Invested Capital (ROIC)0.30
Return on Capital Employed (ROCE)-0.93
Revenue Per Employee1.16M
Employee Count420.00
Inventory Turnover2.20

Taxes

CNY

Over the twelve months ended September 30, 2026, Beijing Leadman Biochemistry Co., Ltd. Class A recorded 9.40M in income tax expense. That works out to an effective tax rate of 57.10, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 16.46M, leaving -8.91M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax9.40M
Effective Tax Rate57.10

Stock Price Statistics

CNY

As of the close on November 17, 2026, Beijing Leadman Biochemistry Co., Ltd. Class A's stock has declined approximately 35.78% over the past 52 weeks. The 50-day moving average sits at 5.88, while the 200-day moving average is 6.23.

52-Week Price Change-35.78%
50-Day Moving Average5.88
200-Day Moving Average6.23

Income Statement

CNY

Over the twelve months ended September 30, 2026, Beijing Leadman Biochemistry Co., Ltd. Class A generated 485.94M in revenue and converted that into -8.91M in net income, yielding earnings per share of 0.01. EBITDA reached 16.70M, while operating income came in at 18.58M.

Revenue485.94M
Gross Profit274.87M
Operating Income18.58M
Pretax Income16.46M
Net Income-8.91M
EBITDA16.70M
EBIT16.70M
Earnings Per Share (EPS)0.01

Balance Sheet

CNY

As of September 30, 2026, Beijing Leadman Biochemistry Co., Ltd. Class A holds 574.79M in cash and equivalents against 982.81M in total debt, resulting in a net debt position of 401.46M. Total book value stands at 1.65B, with working capital of 1.44B providing operational flexibility.

Cash & Cash Equivalents574.79M
Total Debt982.81M
Net Debt401.46M
Equity (Book Value)1.65B
Book Value Per Share3.03
Working Capital1.44B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-33.44M

Margins

Over the twelve months ended September 30, 2026, Beijing Leadman Biochemistry Co., Ltd. Class A posted a gross margin of 56.57, reflecting its pricing power and cost economics. The operating margin of 3.82 and net profit margin of -1.83 provide insight into operational efficiency.

Gross Margin56.57
Operating Margin3.82
Pretax Margin3.39
Profit Margin-1.83
EBITDA Margin3.44

Dividends & Yields

These figures cover the twelve months ended September 30, 2026. Total shareholder yield is negative at -29.18, meaning Beijing Leadman Biochemistry Co., Ltd. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-29.18

Stock Splits

Beijing Leadman Biochemistry Co., Ltd. Class A's most recent stock split took place on October 27, 2015 with a 2:5 split ratio.

Last Split Date10/27/2015
Split Ratio2:5

Scores

As of September 30, 2026, Beijing Leadman Biochemistry Co., Ltd. Class A has an Altman Z-Score of 2.43, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score2.43